Aug 15 (Reuters) - Incyte ( INCY ) said on Thursday its

drug met the main goal in a late-stage trial evaluating it in

patients with a form of blood cancer.

The company said its drug Monjuvi, combined with Bristol

Myers Squibb's ( BMY ) drug, Revlimid, and Biogen's

Rituxan achieved progression free survival in patients with

follicular lymphoma (FL), when compared to Rituxan and Revlimid

alone.

FL is a slow-growing type of non-Hodgkin lymphoma, a cancer

that starts in the body's white blood cells called lymphocytes.

The disease affects about 17,000 people in the U.S.

annually, according to company estimates.

Monjuvi combined with Revlimid is already approved for the

treatment of diffuse large B-cell lymphoma, which is also a

subtype of non-Hodgkin lymphoma.

Based on the results of this trial, Incyte ( INCY ) expects to file a

supplemental marketing application to the FDA by the end of the

year.

Other treatment options for patients with follicular

lymphoma include cell therapies such as Novartis'

Kymriah, Gilead Sciences' ( GILD ) Yescarta and Bristol Myers

Squibb's ( BMY ) Breyanzi.